OPA1 in Cardiovascular Health and Disease

被引：18

作者：

Burke, Niall ^{[1
]}

Hall, Andrew R. ^{[1
]}

Hausenloy, Derek J. ^{[1
,2
,3
]}

机构：

[1] UCL, Hatter Cardiovasc Inst, 67 Chenies Mews, London WC1E 6HX, England

[2] Duke NUS Grad Med Sch, Cardiovasc & Metab Disorders Program, Singapore, Singapore

[3] Natl Heart Ctr, Natl Heart Res Inst Singapore, Singapore, Singapore

来源：

CURRENT DRUG TARGETS | 2015年 / 16卷 / 08期

基金：

英国医学研究理事会;

关键词：

Cardiovascular disease; fission; fusion; mitochondrial morphology; OPA1; DOMINANT OPTIC ATROPHY; CYTOCHROME-C RELEASE; MITOCHONDRIAL PROTEASE OMA1; DYNAMIN-RELATED PROTEIN; PROTEOLYTIC CLEAVAGE; OXIDATIVE-PHOSPHORYLATION; RESPIRATORY-CHAIN; GTPASE OPA1; FUSION; MORPHOLOGY;

D O I：

10.2174/1389450116666150102113648

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Mitochondria are known to play crucial roles in normal cellular physiology and in more recent years they have been implicated in a wide range of pathologies. Central to both these roles is their ability to alter their shape interchangeably between two different morphologies: an elongated interconnected network and a fragmented discrete phenotype - processes which are under the regulation of the mitochondrial fusion and fission proteins, respectively. In this review article, we focus on the mitochondrial fusion protein optic atrophy protein 1 (OPA1) in cardiovascular health and disease and we explore its role as a potential therapeutic target for treating cardiovascular and metabolic disease.

引用

页码：912 / 920

页数：9

共 50 条

[1] Mitochondrial dynamics and disease, OPA1
Olichon, Aurelien
Guillou, Emmanuelle
Delettre, Cecile
Landes, Thomas
Arnaune-Pelloquin, Laetitia
Emorine, Laurent J.
Mils, Valerie
Daloyau, Marlene
Hamel, Christian
Amati-Bonneau, Patrizia
Bonneau, Dominique
Reynier, Pascal
Lenaers, Guy
Belenguer, Pascale
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2006, 1763 (5-6): : 500 - 509
[2] OPA1 in Lipid Metabolism: Function of OPA1 in Lipolysis and Thermogenesis of Adipocytes
Chu, Dinh-Toi
Tao, Yang
Tasken, Kjetil
HORMONE AND METABOLIC RESEARCH, 2017, 49 (04) : 276 - 285
[3] OPA1 (dys)functions
Landes, Thomas
Leroy, Ingrid
Bertholet, Ambre
Diot, Alan
Khosrobakhsh, Farnoosh
Daloyau, Marlene
Davezac, Noelie
Miquel, Marie-Christine
Courilleau, Delphine
Guillou, Emmanuelle
Olichon, Aurelien
Lenaers, Guy
Arnaune-Pelloquin, Laetitia
Emorine, Laurent J.
Belenguer, Pascale
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY, 2010, 21 (06) : 593 - 598
[4] MUTATIONS IN OPA1 EXPAND THE CLINICAL PHENOTYPE OF MITOCHONDRIAL DISEASE
Chinnery, P.
Jackson, M.
Amati-Bonneau, P.
Yu-Wai-Man, P.
Gorman, G.
Duffey, P.
Baker, M.
Zeviani, M.
Horvath, R.
Miller, J.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2010, 81 (11): : E32 - E33
[5] OPA1 processing in cell death and disease - the long and short of it
MacVicar, Thomas
Langer, Thomas
JOURNAL OF CELL SCIENCE, 2016, 129 (12) : 2297 - 2306
[6] Effect of Opa1 on bone remodeling
Jin, Wei
Li, Huijuan
Liu, Jingnan
Liu, Yichen
Han, Dongxu
Song, Lige
JOURNAL OF BONE AND MINERAL RESEARCH, 2024, 39 : 191 - 192
[7] Dominant optic atrophy family with a microdeletion at 3q28 encompassing the OPA1 gene: Evidence that haploinsufficiency of OPA1 is the cause of disease
Marchbank, NJ
Leek, JP
Craig, JE
Toohey, M
Churchill, AJ
Mackey, DA
Markham, AF
Toomes, C
Inglehearn, CF
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2002, 43 : U174 - U174
[8] Mitochondrial Function: OMA1 and OPA1, the Grandmasters of Mitochondrial Health
McBride, Heidi
Soubannier, Vincent
CURRENT BIOLOGY, 2010, 20 (06) : R274 - R276
[9] Extramitochondrial OPA1 and adrenocortical function
Fueloep, Laszlo
Rajki, Aniko
Katona, David
Szanda, Gergoe
Spaet, Andras
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2013, 381 (1-2) : 70 - 79
[10] Focus on molecules: The OPA1 protein
Davies, Vanessa
Votruba, Marcela
EXPERIMENTAL EYE RESEARCH, 2006, 83 (05) : 1003 - 1004

← 1 2 3 4 5 →